Endocrine & Metabolic Disorders
ICON's endocrine and metabolic trial experience, supported by a global team of experts
Obesity and beyond
Embracing multi-indication potential during clinical development
The obesity therapeutic marketplace has rapidly embraced multi-indication drug development, following successful label expansion of incretin agonists semaglutide and tirzepatide. Explore the rise of multi-indication drug development across cardiometabolic-related conditions and the strategies driving clinical and commercial success for molecules with broad potential.
.jpeg?crop=yes&w=1017&h=1017&a=325,0&itok=orjNUe1P "obesity_scan_icons"){kind=icon}
Survey report
How today’s obesity developers are navigating a multi-indication landscape
From January 24 to March 5, 2025, ICON conducted a survey of 155 developers in obesity and related comorbidities. Survey respondents shared their clinical development and commercialisation strategies for molecules with broad clinical and commercial potential, and factors influencing whether or not to pursue multi-indication development of agents in their pipeline.
.jpeg?crop=yes&w=1251&h=1251&a=399,0&itok=eYBdFk5s "obesity scan person"){kind=icon}
A multifaceted risk factor:
Addressing obesity's impact across the disease spectrum
Obesity is a growing health concern worldwide, with at least 2.8 million people dying each year because of the disease. Explore the implications of obesity as a risk factor across the disease spectrum, and how this may impact treatment, drug development and clinical trials for obesity.
ICON survey report:
Trends and challenges in obesity research and clinical trials
Explore the ICON survey of global industry professionals currently engaged in obesity-related clinical research. Respondents were from organisations ranging from small biotechs to large pharmaceutical companies, as well as academic organisations. The survey was designed to measure industry opinions on trends and challenges for the sector.
Webinar: Addressing the challenges of Type 2 Diabetes global clinical trials via high quality lab solutions
Join ICON’s expert Dr. Andrew Roche, PhD as he speaks about overcoming challenges when developing Diabetes trials. Addressing these challenges via use of high quality tools is critical to successful completion of a clinical trial.
Webinar: Digital solutions to alleviate NASH clinical trial challenges
Find out more about the ability for digital technologies including magnetic resonance imaging (MRI), magnetic resonance elastography (MRE) and whole slide imaging (WSI) to address NASH clinical trial challenges.
Endocrine and metabolic disorders blogs and media contributions
-
.jpeg?crop=yes&w=545&h=286&itok=tXlgRb-d "obesity_scan_icons")
Media article: Obesity therapies and the multi-indication momentum: how industry is responding
The rise of GLP-1 agonist therapies has transformed obesity treatment, delivering unprecedented results and revealing their potential across a spectrum of interconnected conditions. New data reveals how the breakthrough has sparked a major shift toward multi-indication drug development.
-
Media article: ICON launches multi-indication trial design service for obesity drugs
Clinical trial designs for obesity treatments should accommodate candidate drugs that have the potential to treat multiple conditions, or developers risk missing opportunities, according to Irish CRO ICON.
-
.jpeg?crop=yes&w=545&h=286&itok=rCH0CGZP "obesity scan person")
Media article: More efficient next-gen obesity clinical trials needed, says survey
In this DDW article, discover key findings of an ICON survey focusing on multi-indication cardiometabolic R&D for therapies targeting obesity and its comorbidities.
-
Media article: Pharma giants eye obesity trial boom — but are they ready for what comes next?
ICON survey shows pharma's enthusiasm for multi-indication obesity trials is outpacing trial design readiness.
-
.jpeg?crop=yes&w=545&h=286&itok=EojYWs74 "obesity scan person")
Press release: Global ICON survey shows need for more efficient obesity clinical trial design
ICON plc today released the findings of a survey of 155 biotech and pharma professionals from across the US and Europe focusing on multi-indication cardiometabolic R&D for therapies targeting obesity and its comorbidities.
-
Media article: The challenge of targeting chronic inflammation in obesity
In this article, ICON experts explore the connection of obesity and inflammation, the current treatment landscape and future treatment directions.
-
Media article: Expanding diagnostic and biomarker options to improve MASH clinical trials
The absence of sufficient and accessible diagnostics for metabolic dysfunction-associated steatohepatitis (MASH) studies can complicate trials and impair clinical study conduct, as diagnostics are essential for disease detection, confirmation, and monitoring.
-
Blog: Obesity-related liver conditions: Understanding treatment options
Explore obesity’s role in liver disease progression and the value of different treatment options providing renewed hope to patients.
.jpeg?crop=yes&w=1665&h=876&a=0,71&itok=-R3klXmC "obesity_scan_icons"){kind=icon}
.jpeg?crop=yes&w=2048&h=1077&a=0,88&itok=QikrQ6DU "obesity scan person"){kind=icon}
.jpeg?crop=yes&w=2048&h=1077&a=0,88&itok=4uJjfwGx "obesity scan person"){kind=icon}
Endocrine & Metabolic Disorders services
ICON is an experienced partner who can assist sponsors in navigating the many challenges of endocrine & metabolic disorders drug development. ICON can help sponsors optimise the clinical trial lifecycle from patient enrolment to payer reimbursement with its customisable solutions and proven strategies. Our highly experienced clinical and therapeutic teams have expertise in conducting trials across a wide range of therapeutic areas including, diabetes, cardiometabolic disorders, gastroenterology, and hepatology.